Shuqing Chen

Shuqing Chen

Auto-generated profile, based on publicly available information

Shuqing Chen

Department of Epidemiology and Biostatistics, School of Public Health, Tongji Medical College, Huazhong University of Science and Technology

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 May 2025 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
LTLimin Tian
Limin Tian
GLGuangyu Long
Guangyu Long
SZSiqi Zhu
Siqi Zhu
YWYuelong Wang
Yuelong Wang
PXPengcheng Xu
Pengcheng Xu
SLSuxin Li
Suxin Li
Imbalanced production and clearance of amyloid-β (Aβ) is a hallmark pathological feature of Alzheimer’s disease (AD). While several monoclonal antibodies targeting Aβ have shown reductions in amyloid burden, their impact on cognitive function remains controversial, with the added risk of inflammatory side effects. Dysregulated stimulator of interferon genes (STING) signaling is implicated in neurodegenerative disorders, yet the biological interaction between this pathway and Aβ, as well as their combined influence on AD progression, is poorly understood. Here, we show that while microglia play a protective role in clearing extracellular Aβ, excessive Aβ engulfment triggers the cytosolic leakage of mitochondrial DNA for cGAS–STING cascade. This creates a negative feedback loop that not only exacerbates neuroinflammation but also impairs further Aβ clearance. To address this, we present a nanomedicine approach termed “Aβ-STING Synergistic ImmunoSilencing Therapy (ASSIST)”. ASSIST comprises STING inhibitors encapsulated within a blood–brain barrier (BBB)-permeable polymeric micelle that also serves as an Aβ scavenger. Through a multivalent interaction mechanism, ASSIST efficiently destabilizes Aβ plaques and prevents monomer aggregation, subsequently promoting the engulfment of the dissociated Aβ by microglia rather than neurocytes. Furthermore, the STING signaling induced by excessive Aβ uptake is blocked, reducing inflammation and restoring microglial homeostatic functions involved in Aβ clearance. Intravenous administration of ASSIST significantly reduces Aβ burden and improves cognition in AD mice, with minimal cerebral amyloid angiopathy or microhemorrhages. We provide a proof-of-concept nanoengineering strategy to target the maladaptive immune feedback loop arising from conventional immunotherapy for AD treatment.

4 January 2021 in The Laryngoscope
Verified
Journal Article
Closed access
PDF file
HBHamza Bhalli
Hamza Bhalli
SCShuqing Chen
Shuqing Chen
ADAndrew Day
Andrew Day
BTBrittny Tillman
Brittny Tillman
EGEli Gordin
Eli Gordin
BSBaran D. Sumer
Baran D. Sumer

15 December 2024 in CPT: Pharmacometrics & Systems Pharmacology
Verified
Journal Article
Open access
SCShuqing Chen
Shuqing Chen
CSChaozhuang Shen
Chaozhuang Shen
YTYuchen Tian
Yuchen Tian
YPYuhe Peng
Yuhe Peng
JHJing Hu
Jing Hu
PYPing Yin
Ping Yin
Topiramate (TPM) is a broad‐spectrum antiepileptic drug (AED) commonly prescribed for approved and off‐label uses. Routine monitoring is suggested for clinical usage of TPM in special population due to its broad side effect profile. Therefore, it is crucial to further explore its pharmacokinetic characteristics. Physio‐chemical properties of TPM were initially determined from online database and further optimized while establishing the PBPK model for healthy adults using the PK‐Sim software. The model was then extrapolated to patients with renal impairment and patients who were hepatically impaired. A drug–drug interaction (DDI) model was also built to simulate plasma TPM concentrations while concomitantly used with carbamazepine (CBZ). The goodness‐of‐fit method and average fold error (AFE) method were used to compare the differences between predicted and observed values to assess the accuracy of the PBPK model. Almost all of the predicted concentration fell within twofold error range of corresponding observed concentrations. The AFE ratio of predicted to observed values of Cmax and AUC0‐inf was all within 0.5 and 2. It is recommended that the doses be reduced to 70%, 50%, and 40% of the healthy adult dose for the chronic kidney disease (CKD) stage 3, stage 4, and stage 5 patients, respectively, and reduced to ~70%, and 35% for the Child–Pugh‐B, and Child–Pugh C scored patient with hepatic impairment, respectively. If TPM is co‐administered with CBZ, increasing TPM doses to 150%–175% of the monotherapy dose is recommended according to model simulation.